Ȥ¹º²Ê

As CEO of the life sciences business for Acacium Group, Paul is responsible for all activities globally in the three relevant brands, which include Ȥ¹º²Ê, Hobson Prior and DRA. He looks after over 280 people, spanning Asia, Europe, and the US, who focus on the biopharmaceutical and medical technology markets in key areas such as regulatory affairs, medical affairs, biometrics and clinical research. The group has been instrumental in helping in the vaccine effort for Covid 19, working with all the main manufacturers. Since  Paul has been with the business it has increased revenue and improved its EBITDA position by 30% making it one of the largest staffing and services businesses globally in the life sciences sector.